心血管

订阅

MedSci主页 / 所有栏目 / 心血管

[OCC2013]稳定型冠心病的诊断策略：斑块稳定并非病情稳定

2013-05-27 OCC2013 OCC2013

OCC2013冠心病缺血性卒中血压
关注

张大东教授：急性缺血性卒中伴冠心病患者的血压问题是一直讨论比较热烈的话题，对于血压的水平控制在什么情况下是最好的，国内外讨论非常多。血压降得比较低一点呢，对有利于缓解卒中病情，但有可能恶化心功能。我个人认为对于这类患者，血压控制在130 mm Hg可能比较好，对于脑卒中患者，有效控制血压有利于脑卒中病情改善，如果低于血压低于120mm Hg实际上不利于脑卒中，我们把血压控制在130/80~85 m

张大东教授：急性缺血性卒中伴冠心病患者的血压问题是一直讨论比较热烈的话题，对于血压的水平控制在什么情况下是最好的，国内外讨论非常多。血压降得比较低一点呢，对有利于缓解卒中病情，但有可能恶化心功能。我个人认为对于这类患者，血压控制在130 mm Hg可能比较好，对于脑卒中患者，有效控制血压有利于脑卒中病情改善，如果低于血压低于120mm Hg实际上不利于脑卒中，我们把血压控制在130/80~85 mm Hg这个水平较合适。

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1803340, encodeId=534418033406f, content=<a href='/topic/show?id=8b44e528972' target=_blank style='color:#2F92EE;'>#稳定型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75289, encryptionId=8b44e528972, topicName=稳定型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Thu Jul 11 00:52:00 CST 2013, time=2013-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799560, encodeId=d6cb1e9956027, content=<a href='/topic/show?id=f9b1e08715e' target=_blank style='color:#2F92EE;'>#病情稳定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70871, encryptionId=f9b1e08715e, topicName=病情稳定)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Fri Feb 07 00:52:00 CST 2014, time=2014-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764949, encodeId=60e11e64949b2, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1dc37824931, createdName=ms7524819409032184, createdTime=Thu Oct 31 19:52:00 CST 2013, time=2013-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329992, encodeId=35681329992ed, content=<a href='/topic/show?id=a91c5e92328' target=_blank style='color:#2F92EE;'>#斑块#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57923, encryptionId=a91c5e92328, topicName=斑块)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Wed May 29 03:52:00 CST 2013, time=2013-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352964, encodeId=f0401352964bc, content=<a href='/topic/show?id=1d931321816' target=_blank style='color:#2F92EE;'>#OCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13218, encryptionId=1d931321816, topicName=OCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed May 29 03:52:00 CST 2013, time=2013-05-29, status=1, ipAttribution=)]
    2013-07-11 108807375_62823127

    #稳定型#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1803340, encodeId=534418033406f, content=<a href='/topic/show?id=8b44e528972' target=_blank style='color:#2F92EE;'>#稳定型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75289, encryptionId=8b44e528972, topicName=稳定型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Thu Jul 11 00:52:00 CST 2013, time=2013-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799560, encodeId=d6cb1e9956027, content=<a href='/topic/show?id=f9b1e08715e' target=_blank style='color:#2F92EE;'>#病情稳定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70871, encryptionId=f9b1e08715e, topicName=病情稳定)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Fri Feb 07 00:52:00 CST 2014, time=2014-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764949, encodeId=60e11e64949b2, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1dc37824931, createdName=ms7524819409032184, createdTime=Thu Oct 31 19:52:00 CST 2013, time=2013-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329992, encodeId=35681329992ed, content=<a href='/topic/show?id=a91c5e92328' target=_blank style='color:#2F92EE;'>#斑块#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57923, encryptionId=a91c5e92328, topicName=斑块)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Wed May 29 03:52:00 CST 2013, time=2013-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352964, encodeId=f0401352964bc, content=<a href='/topic/show?id=1d931321816' target=_blank style='color:#2F92EE;'>#OCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13218, encryptionId=1d931321816, topicName=OCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed May 29 03:52:00 CST 2013, time=2013-05-29, status=1, ipAttribution=)]
    2014-02-07 xsm918

    #病情稳定#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1803340, encodeId=534418033406f, content=<a href='/topic/show?id=8b44e528972' target=_blank style='color:#2F92EE;'>#稳定型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75289, encryptionId=8b44e528972, topicName=稳定型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Thu Jul 11 00:52:00 CST 2013, time=2013-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799560, encodeId=d6cb1e9956027, content=<a href='/topic/show?id=f9b1e08715e' target=_blank style='color:#2F92EE;'>#病情稳定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70871, encryptionId=f9b1e08715e, topicName=病情稳定)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Fri Feb 07 00:52:00 CST 2014, time=2014-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764949, encodeId=60e11e64949b2, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1dc37824931, createdName=ms7524819409032184, createdTime=Thu Oct 31 19:52:00 CST 2013, time=2013-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329992, encodeId=35681329992ed, content=<a href='/topic/show?id=a91c5e92328' target=_blank style='color:#2F92EE;'>#斑块#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57923, encryptionId=a91c5e92328, topicName=斑块)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Wed May 29 03:52:00 CST 2013, time=2013-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352964, encodeId=f0401352964bc, content=<a href='/topic/show?id=1d931321816' target=_blank style='color:#2F92EE;'>#OCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13218, encryptionId=1d931321816, topicName=OCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed May 29 03:52:00 CST 2013, time=2013-05-29, status=1, ipAttribution=)]
    2013-10-31 ms7524819409032184

    #病情#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1803340, encodeId=534418033406f, content=<a href='/topic/show?id=8b44e528972' target=_blank style='color:#2F92EE;'>#稳定型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75289, encryptionId=8b44e528972, topicName=稳定型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Thu Jul 11 00:52:00 CST 2013, time=2013-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799560, encodeId=d6cb1e9956027, content=<a href='/topic/show?id=f9b1e08715e' target=_blank style='color:#2F92EE;'>#病情稳定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70871, encryptionId=f9b1e08715e, topicName=病情稳定)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Fri Feb 07 00:52:00 CST 2014, time=2014-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764949, encodeId=60e11e64949b2, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1dc37824931, createdName=ms7524819409032184, createdTime=Thu Oct 31 19:52:00 CST 2013, time=2013-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329992, encodeId=35681329992ed, content=<a href='/topic/show?id=a91c5e92328' target=_blank style='color:#2F92EE;'>#斑块#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57923, encryptionId=a91c5e92328, topicName=斑块)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Wed May 29 03:52:00 CST 2013, time=2013-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352964, encodeId=f0401352964bc, content=<a href='/topic/show?id=1d931321816' target=_blank style='color:#2F92EE;'>#OCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13218, encryptionId=1d931321816, topicName=OCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed May 29 03:52:00 CST 2013, time=2013-05-29, status=1, ipAttribution=)]
    2013-05-29 ms3994565386320060

    #斑块#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1803340, encodeId=534418033406f, content=<a href='/topic/show?id=8b44e528972' target=_blank style='color:#2F92EE;'>#稳定型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75289, encryptionId=8b44e528972, topicName=稳定型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Thu Jul 11 00:52:00 CST 2013, time=2013-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799560, encodeId=d6cb1e9956027, content=<a href='/topic/show?id=f9b1e08715e' target=_blank style='color:#2F92EE;'>#病情稳定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70871, encryptionId=f9b1e08715e, topicName=病情稳定)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Fri Feb 07 00:52:00 CST 2014, time=2014-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764949, encodeId=60e11e64949b2, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1dc37824931, createdName=ms7524819409032184, createdTime=Thu Oct 31 19:52:00 CST 2013, time=2013-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329992, encodeId=35681329992ed, content=<a href='/topic/show?id=a91c5e92328' target=_blank style='color:#2F92EE;'>#斑块#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57923, encryptionId=a91c5e92328, topicName=斑块)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Wed May 29 03:52:00 CST 2013, time=2013-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352964, encodeId=f0401352964bc, content=<a href='/topic/show?id=1d931321816' target=_blank style='color:#2F92EE;'>#OCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13218, encryptionId=1d931321816, topicName=OCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed May 29 03:52:00 CST 2013, time=2013-05-29, status=1, ipAttribution=)]
    2013-05-29 zhaojie88

    #OCC#

    0

相关资讯

[OCC2013]新型抗凝药物在房颤治疗中的应用与评价

2013年5月24日下午，在第七届东方心脏病学会议心脏节律论坛上，来自解放军总医院的王玉堂教授就新型抗凝药物在房颤治疗中的应用做了精彩的专题报告。目前新型抗凝药物的上市，包括达比加群、利伐沙班、阿哌沙班，给我国的医生和房颤患者带来了福音。同华法林相比，新型抗凝药物具备起效快，半衰期相对较短。王教授详细解读了有关新型抗凝药物的临床试验，包括RE-LY试验（达比加群）、ARISTOTLE试验（阿哌沙班

[OCC2013]稳定型冠心病的诊断策略：病情决定治疗决策

稳定型冠心病指的是斑块大部分是稳定的，如果无引起足够的狭窄或者冠脉血流受阻，那么患者应该以内科药物干预动脉粥样硬化，控制危险因素，加强他汀类治疗为主。临床实践以及临床研究均证实了他汀类药物、抗血小板药物、抗凝药物等药物能有效降低冠心病死亡率。但是所谓稳定与不稳定都是相对的，正如我们所说的运动和静止一样，不能偷换这个哲学的基本概念，其二，稳定型冠心病在一定程度上能转变成不稳定型冠心病，虽然稳定型冠心

[OCC2013]血栓论坛热点

第七届东方心脏病学会议于2013年5月23日-5月26日在上海市世博中心举行，5月25日的血栓病论坛由华东医院郭新贵主任和同济大学附属东方医院刘学波主任担任坛主。近年来抗凝、抗栓治疗指南的更新以及新型药物的不断推出使得血栓的处理成为了心内科医师关注的热点。此次论坛邀请了中山医院的钱菊英教授、瑞典的Michael Fu教授就冠心病抗栓治疗现状与指南更新以及目前欧洲抗栓治疗方案等做了精彩的演讲，使大家

[OCC2013]稳定型冠心病的诊断策略：心肌是否缺血是决策之本

很重要一点，需要评估稳定型心绞痛的患者是否存在心肌缺血，心肌缺血的面积有多大。稳定型心绞痛患者的远期死亡率随缺血面积增大而增高，缺血面积的减少可显著降低死亡率，而血运重建较药物治疗在降低缺血面积方面更有效。既往评估缺血情况更多的是无创的运动负荷心电图试验、运动负荷超声、核素心肌显像等，但有很多患者在进入导管室前缺乏这些检查结果就直接进行冠脉造影进行评估，所幸目前临床上有了较好的在导管室中评估狭窄病

[OCC2013]德国柏林心脏中心TAVI经验

经导管主动脉瓣置入术（TAVI）是目前国际上心脏介入最热门的几个方向之一。来自德国心脏中心的翁渝国教授对他们中心的TAVI经验作了精彩的总结报道。首先，翁教授建议TAVI手术团队应该是个多学科合作团队，应涵盖心外科医师、心内科医师、麻醉医师、心超医师等，最好在杂交手术室进行。接着，翁教授对Edwards和CoreValve两种TAVI瓣膜系统的发展历史总了简介。报告最精彩部分是翁教授对他们中心一些

[OCC2013]心衰论坛病例讨论

第七届东方心脏病学会议心力衰竭论坛第二天，会场学术氛围浓厚，聚集了来自全国各地的专家，对经典病例进行分享。1.本次论坛病例讨论环节，有一大亮点：汇报的病例对“心机淀粉样变性”有更多的关注。从病例和各点评专家的热烈讨论中，参会人员收获颇丰，对心肌淀粉样病变有了更深的认识。 2.来自大连的王珂教授，报告了一例关于“左右心室相互作用”的病例，从病史、体征、临床辅助检查等进行详细解析，并与周京敏教授、李新